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Abstract Purpose of this work was to test the eVect of
tumour-cell-derived keratinocyte growth factor (KGF) or
recombinant KGF (palifermin) on cell proliferation and
radiation response of human HNSCC cells and normal
keratinocytes in vitro. Four tumour cell cultures derived
from head and neck squamous cell carcinomas, primary
keratinocytes, and immortalized keratinocytes were ana-
lysed. Fibroblasts, the natural source of KGF protein,
served as controls. KGF expression was observed in pri-
mary and immortalized keratinocytes, Wbroblasts, and in
tumour cells, while signiWcant KGF receptor expression
was only found in keratinocytes. Recombinant KGF as well
as tumour-cell-derived KGF caused a signiWcant growth
stimulation and radioprotection in keratinocytes, which was
abolished by a neutralizing anti-KGF antibody. This indi-
cates that tumour-cell-derived KGF is biologically active.
In the tumour cell lines, no signiWcant growth stimulation
was induced by recombinant KGF, and the neutralizing
antibody did not inXuence tumour cell growth or radiation
response. Our results indicate that the normal, paracrine
KGF regulatory mechanisms, which are based on KGF
receptor expression, are lost in malignant cells, with the
consequence of irresponsiveness of the tumour cells to
exogenous KGF. In face of the amelioration of the radiation
response of normal epithelia, demonstrated in various clini-
cal and various preclinical animal studies, recombinant
KGF represents a candidate for the selective protection of
normal epithelia during radio(chemo) therapy of squamous
cell carcinoma.
Introduction
Oropharyngeal mucositis is a frequent and dose-limiting
early side eVect in radiotherapy of head and neck cancer.
Severe mucositis causes nutritional insuYciency, pain, and
susceptibility to infection, which aVect patients’ compli-
ance to the treatment. It often necessitates interruption or
cessation of the prescribed therapy, with the consequence
of a substantial decrease in local control probability. Ame-
lioration of the mucosal response, aiming at avoiding ther-
apy interruptions, could thus increase the therapeutic ratio
of radiotherapy of head and neck malignancies. A large
variety of strategies have been tested for this purpose in
recent years, both in patients and in animal models (Dorr
2003; Epstein and Klasser 2006; Keefe et al. 2007). How-
ever, apart from improvement of oral hygiene, adequate
pain medication and antibiotic/antimycotic treatment, none
of these approaches has so far been established in clinical
routine, indicating their relative ineVectiveness.
Keratinocyte growth factor [KGF; also termed Wbroblast
growth factor 7 (FGF7)] is predominantly produced by
cells of mesenchymal origin and acts exclusively through a
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speciWc KGF receptor [Wbroblast growth factor receptor
(FGFR2b)], which is expressed primarily by epithelial
cells. KGF regulates epithelial proliferation, diVerentiation,
and migration and has an important role in epithelial wound
repair. This growth factor hence represents a paracrine mes-
enchymal–epithelial mediator. A truncated recombinant
form of human KGF (23-rHuKGF, palifermin) has been
shown to signiWcantly ameliorate the acute radiation
response of various epithelial tissues (mouse tongue, intes-
tine, salivary glands, airways, urinary bladder) in animal
models (Danilenko 1999; Dorr et al. 2002a, b, c; Dorr et al.
2005b, c; Dorr et al. 2001; Farrell et al. 1998, 1999; Flei-
scher and Dorr 2006; Jaal and Dorr 2007; Khan et al. 1997;
Kilic et al. 2007; Lombaert et al. 2008; OkunieV et al.
2001). More important, this protective eYcacy of recombi-
nant KGF for normal epithelial tissues has been conWrmed
in combination with conditioning treatment for progenitor
cell transplantation for haematological malignancies (Spiel-
berger et al. 2004) as well as for radio(chemo) therapy for
head-and-neck tumours in Wrst clinical studies (Brizel et al.
2008; Meropol et al. 2003). The detailed mechanisms,
through which KGF exerts the protective eVect, currently
remain unclear.
One major concern with respect to the clinical use of
recombinant KGF in combination with the treatment of
solid epithelial malignancies is that the agent may not only
protect normal epithelia but also the tumour. Most of the
studies which tested the eVect of recombinant KGF on
tumour cell survival after treatment with anticancer drugs
or radiation did not demonstrate any substantial protective
activity. Similarly, no signiWcant eVect of recombinant
KGF was demonstrated in animal tumour models; yet these
studies used tumour growth delay rather than tumour cure
as the endpoint [reviewed in (Dorr 2003)]. However, some
experiments suggested that recombinant KGF might have
antiapoptotic activity [reviewed (Finch and Rubin 2006)].
We showed previously that the addition of recombinant
KGF to the medium of early passage HNSCC and lung
tumour cell cultures does not aVect radiation-induced
impairment of proliferation nor clonogenic cell survival
(Hille et al. 2003). These tumour cells expressed KGF
mRNA and protein, and low levels of KGF receptor
mRNA. One plausible explanation for the lacking eVect of
KGF was the very low level of KGF receptor mRNA
expression in the tumour cells. Moreover, the endogenous
KGF expression by the tumour cells may render them inde-
pendent of exogenous KGF signalling, thus suggesting
replacement of the normal paracrine with an autocrine
mechanism in case of malignant growth.
Whether this KGF expressed in tumour cells is biologi-
cally active, remains unclear. Therefore, the aim of the
present study was to evaluate the eVect of recombinant
KGF and tumour-cell-derived KGF on cell proliferation
and radiation response in human epithelial tumour cells and
normal keratinocytes in vitro.
Materials and methods
Cell culture
All cells were cultured at 37°C in a 5% CO2 atmosphere.
Three tumour cell lines, ZMK-1, BW-255, and GR-145,
were derived from human squamous cell carcinomas of the
oropharynx, one cell line, OH-65, was derived from the
hypopharynx. At least 500 mg of tumour material were
disaggregated and cultured in complex medium consisting
of Dulbecco’s minimal essential medium (DMEM) and
Ham’s F12 (50:50), 15% foetal calf serum (FCS), 0.5 g/
ml hydrocortisone, 2 ng/ml epidermal growth factor, 5 g/
ml insulin, antibiotics, and fungizone. For tumour cell cul-
ture, a viable cell count was obtained by trypan blue exclu-
sion. In culture Xasks, 100,000 cells/ml medium were
placed, with twice weekly change of medium and grown to
conXuence. Cell stocks were stored in liquid nitrogen in
their 1st to 3rd passage.
Primary keratinocytes were isolated from skin biopsies
obtained during dermatological surgery. Fat and connective
tissue was removed, and the skin biopsy was dissected into
0.5-cm2 pieces. The samples were washed in gentamycine
(0.2 g/ml) three times for 10 min and incubated in therm-
olysine (0.5 mg/ml) overnight at 4°C. Then the epidermis
was dispatched from the dermis and collected in 0.04%
EDTA. An equal volume of preheated 0.1% trypsin/EDTA
was added and the epidermis was incubated for 6 min at
37°C. Within these 6 min, the probe was shaken every
2 min. The trypsin reaction was stopped by addition of an
adequate volume of DMEM/10% FCS. Cells were spun
down (200 £ g, 10 min) and resuspended in 1–2 ml kerati-
nocyte growth medium (Promocell GmbH, Heidelberg,
Germany) consisting of Keratinocyte Basal Medium, 0.4%
Bovine Pituitary Extract, 0.125 ng/ml Epidermal Growth
Factor, 5 g/ml human Insulin, 0.33 g/ml Hydrocortison,
10 g/ml Transferrin, 0.39 g/ml Epinephrine and 0.15 mM
CaCl. Primary keratinocytes were used in their 2nd to 4th
passage.
HaCat cells (immortalized keratinocytes), originally
generated by Boukamp and Fusenig (Boukamp et al. 1988)
were purchased through CLS Cell Line Services Eppel-
heim, Germany. They were cultured in medium consisting
of DMEM and 10% FCS.
Primary  Wbroblasts, the natural source of KGF, were
derived from a biopsy of a healthy male donor by out-
growth technique and used in their 3rd–5th passage. They
were cultured in medium consisting of DMEM and 10%
FCS.Radiat Environ Biophys (2010) 49:261–270 263
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The use of tumour material and skin biopsies was
approved by the ethical committee of the Medical Faculty
of the Georg-August-Universität Göttingen (no. 6/6/96),
and healthy volunteers and patients gave their informed
consent.
Keratinocyte growth factor (23-rHuKGF, Palifermin)
Amgen Inc., Thousand Oaks, CA, kindly supplied lyophi-
lized recombinant KGF [truncated (23-rHuKGF (Palifer-
min)]. The recombinant human growth factor was produced
in Escherichia coli, puriWed to homogeneity by conven-
tional chromatography, and tested for the presence of endo-
toxin by the company. The lyophilizate was Wrst dissolved
in aqua ad injectabile and then further diluted in culture
medium. The Wnal solution was freshly prepared before
each experiment, and Wnal concentrations from 0.2–1 g/ml
were used.
Irradiation
Cells were irradiated with 200 kV X-rays at a dose rate of
1.25 Gy/min. Radiation doses of 1 and 4 Gy were given as
single doses. Cells were irradiated as suspension and plated
for the respective experiments immediately after irradia-
tion. Sham-irradiated cultures served as speciWc controls.
Determination of the amount of KGF in cell culture 
supernatants
The amount of KGF protein was determined in cell culture
supernatants by the QuantikineTM Human KGF (FGF-7)
Immunoassay (DKG00), R & D Systems, Minneapolis,
USA, according to recommended protocol. For experi-
ments, tumour cells, keratinocytes, or Wbroblasts (100,000
cells/well) were seeded on 12-well plates (Nalge Nunc Int.,
Rochester, NY) in their speciWc medium and allowed to
attach for 24 h. Thereafter, the medium was replaced by the
KGF-free medium used for keratinocyte culture, and the
cells were incubated for further 72 h. For KGF measure-
ment, supernatants were collected, and particulates were
removed by centrifugation.
Western blot
The expression of KGF and KGF receptor in tumour cell
lines, primary Wbroblasts, primary keratinocytes, and HaCat
cells was tested by Western Blot analysis. Cells grown to
80% conXuence in 25-cm2 culture Xasks were washed with
cold PBS and then scraped in a small volume of PBS. After
lysis and whole protein content determination, proteins
were separated by 10% SDS–PAGE and subsequently elec-
trotransferred onto nitrocellulose membranes. For protein
detection, the WesternBreeze Chromogenic Immunodetec-
tion System (Invitrogen, Carlsbad, USA) was used follow-
ing the instructions of the manufacturer. Primary antibodies
were for KGF MAB2511 Clone 29568, dilution 1:250; for
KGF receptor MAB665 Clone 98707, dilution 1:250 (both
R&D Systems) and for actin IgG1, dilution 1:1,000 (Santa
Cruz, Santa Cruz, USA). Incubation time for these antibod-
ies was 90 min.
Real-time PCR
Relative quantiWcation of mRNA expression for KGF and
KGF receptor was performed with SYBR Green PCR Mas-
ter Mix (Eurogentec, Seraing, Belgium) using a thermal
cycler ABI PRISM 7700 (Perkin-Elmer-Applied Biosyn-
thesis, Foster City, CA). Total RNA was isolated from
tumour cell lines, HaCat cells, and primary keratinocytes
with the RNeasy Mini Kit (Qiagen) according to the manu-
facturer’s instructions. Aliquots of 1 mg of total RNA, ran-
dom primers, and Moloney murine leukaemia virus reverse
transcriptase (Invitrogen) were used for cDNA synthesis.
The PCR was done with cDNA aliquots and primer
sequences speciWc for human KGF, KGF receptor, and
-actin. Primer sequences are available upon request.
Relative quantiWcation of target gene expression was calcu-
lated by the comparative threshold cycle (Ct) method.
CellTiterBlue viability test
The CellTiterBlue viability assay from Promega (Promega
Corporation, Madison, WI, USA), a method for estimating
the number of viable cells present in a given cell popula-
tion, was used according to the manufacturer’s instructions.
Cells were grown in 96-well tissue culture plates in 100 l
culture medium, and cell viability was tested after 24, 48,
72, and, 96 h at 37°C. For this, cells were incubated with
20 l CellTiterBlue reagent for 3.5 h, and results were
recorded at 570 nm wavelength (reference 600 nm) using a
plate reader (GENIOS PLUS, Tecan Deutschland GmbH,
Crailsheim, Germany). To test for stimulating eVects of
KGF, cells were either plated in cell culture supernatants
obtained as described under “Determination of the amount
of KGF in cell culture supernatants” or in rHuKGF-con-
taining medium at concentrations from 0.2 to 1 g/ml rHu-
KGF. For neutralization experiments, KGF antibody
(MAB251 Clone 29522) at a concentration of 2 g/ml was
added to the cell culture medium (supernatants) 1 h before
plating. This antibody concentration had previously been
demonstrated to be suYcient for the neutralization of 15–
25 ng KGF. Cell cultures treated with unspeciWc IgG
antibodies served as respective controls. Experiments were
performed in triplicate and repeated 3–4 times, and for
analysis, data were normalized to the 24-h records.264 Radiat Environ Biophys (2010) 49:261–270
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Data analysis
Means and standard errors were calculated for each of the
data points; statistical comparison was done using the t-test
for each dose point. Statistical comparison was performed
between cultures treated with rHuKGF, tumour-derived
KGF and no KGF; cultures treated with or without anti-
body, and irradiated and non-irradiated cells. All analyses
were performed with KaleidaGraph™ 3.5, Synergy Soft-
ware, Reading PA, USA.
Results
Detection of KGF in supernatants of tumour cell lines 
and Wbroblasts by ELISA
The secretion of KGF protein into the culture medium was
tested for Wbroblasts (DF-19), tumour cell cultures (BW-
225, GR-145, OH-65, ZMK-1), and immortalized keratino-
cytes (HaCat) by ELISA. All supernatants contained KGF,
the highest KGF concentrations being found for ZMK-1
and BW-225 cells. Table 1 lists the measured concentra-
tions.
Detection of KGF and KGF receptor in tumour cell lines, 
Wbroblasts and keratinocytes by western blot and real-time 
PCR
Intracellular KGF was detected in Wbroblasts (DF19), the
tumour cell cultures (BW-225, GR-145, OH-65, ZMK-1),
and primary and immortalized (HaCat) keratinocytes.
A typical Western Blot is shown in Fig. 1a.
In contrast, KGF receptor, at the expected molecular
weight, was only detected in keratinocytes. Some tumour
cells showed bands at higher molecular weights, which
might represent aberrant receptor forms or unspeciWc sig-
nals. An example is shown in Fig. 1b.
Real-time PCR was performed to test for radiation-
induced changes in KGF and KGF receptor mRNA expres-
sion. In accordance with the western blot results, KGF
mRNA expression was found in Wbroblasts (DF-19), all
tumour cell lines (BW-225, GR-145, OH-65, ZMK-1), and
primary and immortalized (HaCat) keratinocytes. Primary
keratinocytes (KTC) as well as HaCat cells showed
increased KGF mRNA expression after irradiation at 6 and
24 h, and at both radiation doses of 1 and 4 Gy. KGF
mRNA expression in Wbroblasts was increased after 24 h.
In tumour cells, up- as well as down-regulation of KGF
mRNA was detected. Figure 2a summarizes the results; the
mRNA expression is normalized to the unirradiated con-
trols.
In accordance with the Western Blot results, signiWcant
KGF receptor mRNA expression was only found in pri-
mary keratinocytes and HaCat cells. Figure 2b shows that
KGF recptor mRNA expression in primary keratinocytes is
upregulated at both time points and radiation doses, while
KGF receptor mRNA expression in HaCat cells is nearly
unaVected by radiation.
Cell proliferation of keratinocytes in response 
to recombinant KGF, cell-derived KGF 
and anti-KGF antibody treatment
Compared to the cell proliferation in KGF-free medium a
signiWcant increase in cell proliferation was observed for
cells treated with 0.2, 0.5, and 1.0 g/ml recombinant KGF.
No signiWcant diVerence in proliferation was found
between the recombinant KGF concentrations. Figure 3a
shows growth curves for keratinocytes incubated in
medium containing 0.2 or 1.0 g/ml recombinant KGF,
respectively. Recombinant KGF-induced increased prolif-
eration was also observed in keratinocytes irradiated at 1 or
4G y  ( F i g .3b). This increased proliferation could be abro-
gated by the addition of a neutralizing anti-KGF antibody.
Data were recorded at 24, 48, 72, and 96 h, and signiWcant
Table 1 KGF concentrations measured in cell culture supernatants









Fig. 1 a Example of KGF 
expression in normal (keratino-
cytes, Wbroblasts DF-19) and 
tumour (ZMK-1, GR-145, 
BW-225, OH-65) cells. b KGF 
receptor expression in keratino-
cytes and ZMK-1 tumour cellsRadiat Environ Biophys (2010) 49:261–270 265
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neutralization occurred at 72 (data not shown) and 96 h. In
this experiment, unspeciWc IgG antibodies were added as
respective controls (Fig. 3b).
To test whether tumour-cell-derived KGF would also stim-
ulate keratinocyte proliferation, keratinocytes were plated in
tumour cell supernatants containing either unspeciWc IgG
antibodies or a speciWc anti-KGF antibody at a concentration
of 2 g/ml antibody, which had previously been determined
to be suYcient for the neutralization of 15–25 ng KGF. Addi-
tion of the speciWc anti-KGF antibody led to a signiWcantly
lower proliferation of keratinocytes plated in DF 19-, ZMK-1
BW-225-, and GR-145 supernatants. For keratinocytes plated
in OH-65 supernatant or KGF-free keratinocyte medium
(KM), the antibody showed no eVect. Data were recorded at
24, 48, 72, and 96 h after plating; signiWcant reduction of
proliferation was observed at 72 h (data not shown) and 96 h;
Fig. 4 a and b show results for cells irradiated at 1 Gy and
4 Gy recorded 96 h after plating.
Cell proliferation of tumour cells and Wbroblasts 
in response to recombinant KGF, cell-derived KGF 
and additional anti-KGF antibody treatment
To test cell proliferation of tumour cells and Wbroblasts in
response to recombinant KGF, both cell types were incu-
bated with 0.2 g/ml recombinant KGF for 72 and 96 h.
Compared to the cell proliferation in KGF-free medium, no
signiWcant increase in proliferation was observed. Figure 5a
shows two growth curves over 72 h, and Fig. 5b summa-
rizes the results recorded at 96 h for all cell lines tested.
Fig. 2 a Radiation-induced changes in KGF expression in normal
(KTC = primary keratinocytes, HaCat = immortalized keratinocytes,
DF-19 = primary Wbroblasts) and tumour cells (BW-225, ZMK-1,
GR-145, OH-65). Error bars represent standard deviations. Measure-
ments were performed in duplicate and experiments were repeated two
times. b Radiation-induced changes in KGF receptor expression in
keratinocytes (KTC) and HaCat cells. Error bars represent standard
deviations. Measurements were performed in duplicate, and experi-
ments were repeated two times
Fig. 3 a Stimulated proliferation of keratinocytes by recombinant
KGF is not concentration dependent. Data were recorded over 96 h,
error bars represent §1 standard deviation; statistically signiWcant
(P · 0.05) stimulation was observed at 72 and 96 h, as marked by
asterisks. Measurements were performed in triplicate, and experiments
were repeated at least three times. b KGF-induced (0.2 g/ml
recombinant KGF) stimulated proliferation of irradiated keratinocytes
was abrogated by the addition of anti-KGF antibody to the medium.
Data shown were recorded after 96 h of incubation. Error bars
represent §1 standard deviation; statistically signiWcant (P · 0.05)
inhibition of proliferation is marked by asterisks. Measurements were
performed in triplicate, and experiments were repeated at least three
times266 Radiat Environ Biophys (2010) 49:261–270
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To test whether the addition of a neutralizing anti-KGF
antibody would inXuence cell proliferation or radiation
response, tumour cells and Wbroblasts were plated in
medium containing either unspeciWc IgG antibodies or a
speciWc anti-KGF antibody at a concentration of 2 g/ml
antibody. Growth data were recorded over 96 h, however,
at no time point and in none of the cell lines impaired pro-
liferation was observed for cells plated in the presence of
the neutralizing antibody. Figure 6a–c summarize the
results obtained for non-irradiated cells, and for cells irradi-
ated at 1 or 4 Gy.
To exclude low antibody concentrations in the medium
as reason for the lack of proliferation impairment, a second
treatment schedule was tested. ZMK-1 cells were incubated
in medium containing 1, 5, 10, or 20 g/ml neutralizing
anti-KGF antibody. Compared to the proliferation in
medium with an unspeciWc IgG antibody, no diVerence in
proliferation was observed after 96 h; additionally, no
diVerence was seen between the various antibody concen-
trations (individual data not shown).
Discussion
The aim of the present study was to evaluate the role of
tumour-cell-derived KGF for cell proliferation and radia-
tion response of human epithelial tumour cells and kerati-
nocytes. The Wndings are of clinical signiWcance and
important for the implementation of KGF in clinical use. In
particular, we found that tumour-cell-derived KGF could
Fig. 4 a Reduced proliferation of keratinocytes in media containing a
speciWc anti-KGF antibody compared to media containing unspeciWc
IgG antibodies. Keratinocytes were plated in supernatants derived
from primary Wbroblasts (DF-19), epithelial tumour cells (BW-225,
ZMK-1, GR-145, OH-65), or KGF-free keratinocyte medium (KM).
Data were recorded for cells irradiated at 1 Gy, 96 h after plating.
Error bars represent §1 standard deviation; statistically signiWcant
(P · 0.05) inhibition of proliferation is marked by asterisks. Measure-
ments were performed in triplicate, and experiments were repeated at
least three times. b Reduced proliferation of keratinocytes in media
containing a speciWc anti-KGF antibody compared to media containing
unspeciWc IgG antibodies. Keratinocytes were plated in supernatants
derived from primary Wbroblasts (DF-19), epithelial tumour cells
(BW-225, ZMK-1, GR-145, OH-65), or KGF-free keratinocyte medi-
um. Data were recorded for cells irradiated at 4 Gy, 96 h after plating.
Error bars represent §1 standard deviation; statistically signiWcant
(P · 0.05) inhibition of proliferation is marked by asterisks. Measure-
ments were performed in triplicate and experiments were repeated at
least 3 times
Fig. 5 a No stimulated proliferation by recombinant KGF added to tu-
mour cell cultures for 72 h. Open symbols represent cells plated in
KGF-free medium; closed symbols represent cells plated in medium
containing 0.2 g/ml recombinant KGF. Data were recorded over 72 h,
error bars represent §1 standard deviation. Measurements were per-
formed in triplicate and experiments were repeated at least three times.
b No eVect of recombinant KGF added to tumour cell cultures for 96 h.
Closed bars represent cells plated in KGF-free medium; horizontal
stripes represent cells plated in medium containing 0.2 g/ml recombi-
nant KGF. Data were recorded over 96 h, error bars represent §1
standard deviation. Measurements were performed in triplicate, and
experiments were repeated at least three timesRadiat Environ Biophys (2010) 49:261–270 267
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stimulate the proliferation of irradiated and unirradiated
keratinocytes, while tumour cell proliferation was not
aVected. To the best of our knowledge, such experiments
have not been performed before.
To demonstrate the applicability of the experimental
approach, Wrst the eVect of recombinant KGF on primary
keratinocytes was tested. Comparable to former results
(Hille et al. 2003; Slonina et al. 2001), increased cell prolif-
eration and altered radiation response was observed for
keratinocytes treated with rHuKGF, the pro-proliferative
eVect being abolished by a neutralizing anti-KGF antibody.
Likewise, the secretion of a protein detectable by a KGF-
speciWc ELISA into the culture medium of Wbroblasts and
epithelial tumour cells was conWrmed. The presence of
KGF protein in tumour cells was further supported by spe-
ciWc signals in Western blots. Analysis of radiation-induced
changes in KGF expression showed mRNA up-regulation
in Wbroblasts and no systematic changes of the regulation in
tumour cells. Unexpectedly, we also found KGF mRNA
and protein expression in primary keratinocytes, RNA
expression being up-regulated by irradiation. For conWrma-
tion, immortalized keratinocytes (HaCat cells) were tested
and showed KGF mRNA expression and secretion as well.
Predominantly, KGF is produced by mesenchymal cells,
and target cells are of epithelial origin. However, KGF pro-
duction by normal epithelial cells has occasionally been
described. One report came from Parrott et al. (2000)
describing KGF expression in normal ovarian surface epi-
thelium, which increased when cells were cultured.
Another report found KGF expression in lung alveolar epi-
thelial cells (Yamayoshi et al. 2004), and recently, Suyama
et al. (2009) reported on the expression of KFG protein in
epithelial cells of odontogenic keratocysts.
KGF detection is more frequent in altered epithelial
cells, e.g. associated with inXammatory and tumorigenic
processes. Bansal et al. (1997) described the expression of
KGF mRNA in human breast cancer cell lines and puriWed
populations of epithelial cells, Shaoul et al. (2006) found
markedly increased KGF protein levels in the mucosal epi-
thelium of patients with gastric inXammation, as well as in
gastric adenocarcinoma. In the prostate, KGF expression is
present in epithelial cells in benign prostate hyperplasia and
prostate cancer (Planz et al. 1999). Likewise, oesophageal
(Yoshino et al. 2007), pancreatic (Siddiqi et al. 1995), and
colorectal (Watanabe et al. 2000) cancer samples revealed
signiWcant expression of KGF mRNA and protein, and pan-
creatic cancer cell lines also expressed KGF mRNA (Sid-
diqi et al. 1995).
KGF interacts only with KGF receptor and is internal-
ized into the cytoplasm by receptor-mediated endocytosis
(Belleudi et al. 2007). Therefore, in studies using immuno-
histochemistry, the immunolocalized KGF in the cytoplasm
of epithelial cells might indicate incorporated KGF through
Fig. 6 a No eVect of the neutralizing anti-KGF antibody on the prolifera-
tion of Wbroblasts (DF-19) or epithelial tumour cells (BW-225, ZMK-1,
GR-145, OH-65) was found. Data were recorded for non-irradiated cells,
96 h after plating. Closed bars represent cells plated in KGF-free medium;
dashed bars represent cells plated in medium containing 0.2 g/ml recom-
binant KGF. Error bars represent §1 standard deviation. Measurements
were performed in triplicate and experiments were repeated at least three
times. b No eVect of the neutralizing KGF antibody on the proliferation of
Wbroblasts (DF-19) or epithelial tumour cells (BW-225, ZMK-1, GR-145,
OH-65) was observed. Data were recorded for cells irradiated with 1 Gy,
96 h after plating. Closed bars represent cells plated in KGF-free medium;
dashed bars represent cells plated in medium containing 0.2 g/ml recom-
binant KGF. Error bars represent §1 standard deviation. Measurements
were performed in triplicate and experiments were repeated at least three
times. c No eVect of the neutralizing KGF antibody on the proliferation of
Wbroblasts (DF-19) or epithelial tumour cells (BW-225, ZMK-1, GR-145,
OH-65) was found. Data were recorded for cells irradiated with 4 Gy, 96 h
after plating. Closed bars represent cells plated in KGF-free medium;
dashed bars represent cells plated in medium containing 0.2 g/ml recom-
binant KGF. Error bars represent §1 standard deviation. Measurements
were performed in triplicate and experiments were repeated at least three
times268 Radiat Environ Biophys (2010) 49:261–270
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KGF receptor. However, where tested, KGF expression
was conWrmed on the RNA level, suggesting true KGF syn-
thesis in epithelial cells. The role of endogenous KGF in
normal epithelial cells may be related to the adaptation to
ex vivo culture conditions.
The expression of the KGF receptor in primary keratino-
cytes was expected and could be shown by Western blot
and real-time PCR. Accordingly, primary keratinocytes
responded to KGF application by increased proliferation. A
comparable stimulation of proliferation was achieved when
keratinocytes were grown in tumour cell culture superna-
tants. Such stimulated proliferation was also observed for
irradiated cultures. Tumour cells are known to secrete
growth factors other than KGF; however, two Wndings sup-
port the assumption that tumour-cell-derived KGF was
causative for the observed stimulated proliferation of kerat-
inocytes. First were the same results achieved with superna-
tant derived from Wbroblast cultures, Wbroblasts being a
natural source of KGF. Second could the stimulated prolif-
eration be abrogated by the application of neutralizing anti-
KGF antibodies. To the best of our knowledge, comparable
experiments have not been reported to date.
In various preclinical and clinical studies (Beaven and
Shea 2007; Brizel et al. 2008; Dorr et al. 2005a, b, c; Dorr
et al. 2001; Dorr et al. 2002c; Farrell et al. 1998; Finch and
Rubin 2006; Kilic et al. 2007; Lombaert et al. 2008; Mero-
pol et al. 2003), KGF was shown to protect patients with
head and neck cancer from adverse (oral mucosal) eVects of
radio- and/or chemotherapy, at least partly based on modiW-
cation of keratinocyte proliferation and presumably diVer-
entiation. As also epithelial tumour cells express the KGF
receptor, one concern with respect to the clinical use of
recombinant KGF is that the agent not only reduces the
response of normal epithelia to the treatment, but also
impacts on the eVect of the treatment on these epithelial
tumours. Therefore, the eVect of recombinant KGF on pro-
liferation in four human epithelial tumour cell cultures was
tested in the present study using the CellTiterBlue viability
assay. Compared to the cell proliferation in KGF-free
medium, no signiWcant increase in proliferation was
observed for tumour cells treated with recombinant KGF.
Likewise, Wbroblasts used as negative control culture were
not responsive to treatment with recombinant KGF. These
results are in accordance with the results of Ning et al.
(1998) and of our former study (Hille et al. 2003). How-
ever, in the present and the former study, tumour cell
cultures in very early passages were used and thus a con-
tamination of the cultures with mesenchymal cells had been
considered as well. To diVerentiate epithelial from mesen-
chymal cells, immunocytochemistry for cytokeratin (pan-
cytokeratin and cytokeratin 4, 5, 6) and vimentin had been
applied (Hille et al. 2003). All tumour cells cultures that
were used in the present study stained positive in both cyto-
keratin assays. A co-expression for vimentin, as it is well
known for some cultured epithelial cells, was observed in
the samples as well. However, there were no cells express-
ing vimentin only, and hence we believe that there was
no noteworthy  Wbroblast contamination in the tumour
samples.
The mechanisms of the eVects of KGF on the various
cells and particularly the diVerences in the responses to
KGF of normal and tumour cells are still not fully under-
stood. The eVect of KGF is mediated by binding to the
KGF receptor, which, in normal cells, binds KGF with high
aYnity. A plausible explanation for the lack of KGF-
induced (recombinant KGF) stimulated proliferation in the
present study as well as for lacking radioprotection in the
former study (Hille et al. 2003) had been the very low level
of KGF receptor mRNA expression in the tumour cell cul-
tures. We now tested whether irradiation would increase the
KGF receptor expression. However, no increase in receptor
mRNA expression after irradiation at 1 or 4 Gy was observed
over 24 h. Others (Drugan et al. 1997; Ning et al. 1998)
found no correlation between KGF cell surface receptor
expression and KGF-induced proliferation.
The proliferation-enhancing eVect of tumour cell super-
natants on primary keratinocytes indicated the production
of a biologically active protein by tumour cells. To validate
that this protein was KGF, tumour cells (irradiated or not)
were cultured in the presence of a neutralizing anti-KGF
antibody. Within 96 h after irradiation and plating, there
were no diVerences in proliferation compared to prolifera-
tion in medium with an unspeciWc IgG-antibody. To elimi-
nate low antibody concentrations as reason for no eVect on
tumour cell growth, increased antibody concentrations were
tested. However, compared to the proliferation in medium
with an unspeciWc IgG-antibody, no diVerence in prolifera-
tion was observed after 96 h, and no diVerence was seen
between diVerent antibody concentrations.
In conclusion, KGF expression was found in primary
and immortalized keratinocytes and in tumour cell cul-
tures established from head and neck cancer, while rele-
vant KGFreceptor expression was only found in
keratinocytes. Stimulated proliferation by either recombi-
nant KGF or tumour-cell-derived KGF was restricted to
keratinocytes. Concerning the mechanism underlying the
diVerences in the responses to KGF of normal and tumour
cells a replacement of the normal paracrine with an auto-
crine mechanism in case of malignant growth seems plau-
sible. Taken together with the positive outcome of clinical
studies and the amelioration of radiation tolerance of nor-
mal epithelia in animal models, these results support
recombinant KGF as a candidate for selective ameliora-
tion of the response of normal epithelia during radiother-
apy of human epithelial tumours, but also after accidental
radiation exposure.Radiat Environ Biophys (2010) 49:261–270 269
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